×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Dr. David Brownstein, M.D
Dr. David Brownstein,  editor of Dr. David Brownstein’s Natural Way to Health newsletter, is a board-certified family physician and one of the nation’s foremost practitioners of holistic medicine. Dr. Brownstein has lectured internationally to physicians and others about his success with natural hormones and nutritional therapies in his practice. His books include Drugs That Don’t Work and Natural Therapies That Do!; Iodine: Why You Need It, Why You Can’t Live Without It; Salt Your Way To Health; The Miracle of Natural Hormones; Overcoming Arthritis, Overcoming Thyroid Disorders; The Guide to a Gluten-Free Diet; and The Guide to Healthy Eating. He is the medical director of the Center for Holistic Medicine in West Bloomfield, Mich., where he lives with his wife, Allison, and their teenage daughters, Hailey and Jessica.

Tags: ALzheimers | amyloid | trial | dementia

Drug Fails Alzheimer's Patients

Dr. Brownstein By Tuesday, 01 September 2020 04:37 PM Current | Bio | Archive

Alzheimer’s disease is the most common form of dementia among older people. The condition is characterized by memory decline that includes difficulty remembering events as well as recognizing family and friends.

When an Alzheimer’s sufferer’s brain is biopsied, the tissue contains many abnormal clumps of protein called amyloid plaques, as well as other tangled bundles of fibers. Scientists have been searching for a cure for decades.

The drug Verubecestat works by inhibiting an enzyme (BACE1) that reduces amyloid in the brain. The results of a phase 3 trial were published in JAMA, showing that Verubecestat reduced amyloid in the cerebrospinal fluid and the brain of subjects, but the clinical outcomes were not changed.

In other words, Alzheimer’s disease progressed among those treated with the medication to reduce amyloid levels.

The authors of the study wrote, “. . . disease progression [in Alzheimer’s disease] may be independent of [amyloid] production or, alternatively, the amyloid hypothesis of Alzheimer’s disease may not be correct.”

This study showed that altering a clinical marker — amyloid levels — in Alzheimer’s did nothing to slow the disease’s progression.

When I first heard about this study, I predicted it would fail. By the time the brain is being remodeled with amyloid plaques and tangles, it may be too late to save it.

Hopefully, this study will spur Alzheimer’s researchers to search for the real underlying mechanism of the disease.

I have maintained for years that toxic exposures coupled with nutritional deficiencies set the stage for chronic diseases like Alzheimer’s. Only when we find the real cause of the illness will we make progress toward curing it.

© 2021 NewsmaxHealth. All rights reserved.


Dr-Brownstein
Alzheimer’s disease is the most common form of dementia among older people. The condition is characterized by memory decline that includes difficulty remembering events as well as recognizing family and friends.
ALzheimers, amyloid, trial, dementia
267
2020-37-01
Tuesday, 01 September 2020 04:37 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved